[go: up one dir, main page]

MX2022015030A - Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide. - Google Patents

Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.

Info

Publication number
MX2022015030A
MX2022015030A MX2022015030A MX2022015030A MX2022015030A MX 2022015030 A MX2022015030 A MX 2022015030A MX 2022015030 A MX2022015030 A MX 2022015030A MX 2022015030 A MX2022015030 A MX 2022015030A MX 2022015030 A MX2022015030 A MX 2022015030A
Authority
MX
Mexico
Prior art keywords
subjects
rheumatoid arthritis
compositions
methods
treating
Prior art date
Application number
MX2022015030A
Other languages
English (en)
Inventor
Hoogstraten Hubert Van
Kerri Ford
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2022015030A publication Critical patent/MX2022015030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere al uso de un anticuerpo anti-receptor de IL6 para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.
MX2022015030A 2020-05-29 2021-05-27 Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide. MX2022015030A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032035P 2020-05-29 2020-05-29
US202063077378P 2020-09-11 2020-09-11
EP21315081 2021-05-11
PCT/IB2021/054652 WO2021240436A1 (en) 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2022015030A true MX2022015030A (es) 2023-01-04

Family

ID=76269781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015030A MX2022015030A (es) 2020-05-29 2021-05-27 Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.

Country Status (12)

Country Link
US (1) US20230192871A1 (es)
EP (1) EP4157450A1 (es)
JP (1) JP2023527200A (es)
KR (1) KR20230018443A (es)
CN (1) CN115697486A (es)
AU (1) AU2021279412A1 (es)
BR (1) BR112022023949A2 (es)
CA (1) CA3180041A1 (es)
CO (1) CO2022017828A2 (es)
IL (1) IL298087A (es)
MX (1) MX2022015030A (es)
WO (1) WO2021240436A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202106712A (zh) 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
MA56116A (fr) 2019-06-04 2022-04-13 Stefano Fiore Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CA2961389A1 (en) * 2014-09-16 2016-03-24 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients

Also Published As

Publication number Publication date
IL298087A (en) 2023-01-01
US20230192871A1 (en) 2023-06-22
BR112022023949A2 (pt) 2022-12-27
AU2021279412A1 (en) 2023-02-02
KR20230018443A (ko) 2023-02-07
EP4157450A1 (en) 2023-04-05
CO2022017828A2 (es) 2022-12-20
CN115697486A (zh) 2023-02-03
CA3180041A1 (en) 2021-12-02
WO2021240436A1 (en) 2021-12-02
JP2023527200A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2022015030A (es) Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.
MX389945B (es) Anticuerpos anti-pd-1 y sus metodos de uso.
PH12022550141A1 (en) Immunomodulatory antibodies and methods of use thereof
PH12023500009A1 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
MX2020008039A (es) Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
MX2020007495A (es) Formulacion de adenovirus del grupo b.
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
MX2022010793A (es) Metodos para refinacion de licores fuertes.
MX2025003476A (es) Anticuerpos anti-il-27 y usos de los mismos
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
MX2021009242A (es) Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica.
CO2021017737A2 (es) Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide
MX2021015336A (es) Dosificacion modificada de tocilizumab subcutaneo para la artritis reumatoide.
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
Ali et al. Predictability of engineering students’ performance at the University of Engineering and Technology, Peshawar from admission test conducted by educational testing and evaluation agency (ETEA), NWFP, Pakistan
MX2023006474A (es) Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico.
EA202192416A1 (ru) Способы лечения субъектов с псориатическим артритом
Bernardi et al. Preface to the Rostock Debate on Demographic Change
HK40091694A (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same